We additionally demonstrated that PPIP5K2 partially controls NSCLC tumorigenesis through the AKT/mTOR signaling pathway via the application of AKT signaling-related agonists or antagonists. This evidence concerns the gene MTOR and non-small cell lung carcinoma.